Effect of Gabapentin on Post-Operative Pain in Minimally Invasive Sacrocolpopexy
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Enhanced recovery after surgery (ERAS) has been synonymous with increasing non-opioid
multimodal therapies and decreasing opioid therapies after surgery to improve perioperative
care. Gabapentin has been standardized as part of routine adjuvant post-operative enhanced
recovery protocols after other surgical specialties surgeries. Limited data is known about
the specifics of routine adjuvant post-operative gabapentin in the realm of urogynecology.
Sacrocolpopexy has been noted as a highly effective prolapse surgical treatment, especially
with apical and multicompartment prolapse. In 2006, approximately 73% of all sacrocolpopexy
across the nation are completed through a minimally invasive approach. The role of gabapentin
as part of a postoperative pain protocol following minimally invasive sacrocolpopexy (MISC)
has yet to be determined.